Nov 10, 2016 • 4:05 pm EST Corbus Pharmaceuticals Reports 2016 Third Quarter Financial Results and Provides Business Update
Oct 18, 2016 • 7:00 am EDT Corbus Pharmaceuticals Receives Orphan Designation for Resunab for the Treatment of Cystic Fibrosis in the European Union
Oct 13, 2016 • 7:30 am EDT Corbus Pharmaceuticals Announces Completion of Phase 2 Study of Resunab for Systemic Sclerosis
Sep 28, 2016 • 7:30 am EDT Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation
Sep 12, 2016 • 7:05 am EDT Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Resunab for the Treatment of Cystic Fibrosis
Aug 15, 2016 • 7:30 am EDT Corbus Pharmaceuticals Reports 2016 Second Quarter Financial Results and Provides Business Update
Jul 6, 2016 • 7:30 am EDT Corbus Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12, 2016
Jun 17, 2016 • 7:00 am EDT Corbus Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 22, 2016
Jun 16, 2016 • 7:00 am EDT Corbus Pharmaceuticals Announces Last Patient Enrolled in Phase 2 Study of Resunab for Systemic Sclerosis